Ionis Pharmaceuticals
IONS
240 hedge funds and large institutions have $4.1B invested in Ionis Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 86 increasing their positions, 85 reducing their positions, and 27 closing their positions.
15% more capital invested
Capital invested by funds: $3.58B → $4.1B (+$523M)
11% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 27
1% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 85
1% more funds holding
Funds holding: 238 → 240 (+2)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
44% less call options, than puts
Call options by funds: $56M | Put options by funds: $101M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$47.2M |
| 2 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
+$33.3M |
| 3 |
ClearBridge Investments
New York
|
+$26.6M |
| 4 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$16.7M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$26.7M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$13.7M |
| 3 |
SI
Scout Investments
Kansas City,
Missouri
|
-$10.8M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$8.05M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$7.62M |
IONS Hedge Fund Activity: Q3 2014 in Review
240 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2014, worth a combined $4.1B — up 15% from $3.58B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new IONS positions and 27 closed out — a net gain of 3 holders — while 86 added to existing stakes and 85 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $47.2M. The largest seller was Norges Bank, cutting an estimated $26.7M.
- 240 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2014, up from 238 in Q2 2014.
- Funds reported $4.1B of Ionis Pharmaceuticals stock for Q3 2014, up 15% quarter-over-quarter.
- 30 funds opened new Ionis Pharmaceuticals positions in Q3 2014 and 27 closed out, a net change of +3 holders.
- The largest Ionis Pharmaceuticals buyer in Q3 2014 was Eagle Asset Management, an estimated $47.2M added.
- The largest Ionis Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $26.7M sold.
Based on aggregated 13F filings for Q3 2014.